Answers are grounded in this paper and cite their sources.
• Chitosan-genipin microencapsulation enhances oral FMT. • Superior protection against gastric acid. • Maintains bacterial viability and function. • Promising non-invasive treatment. Fecal microbiota transplantation (FMT) constitutes a practical therapeutic approach for a range of gastrointestinal disorders; nonetheless, its predominant delivery method, colonoscopy, limits its broader application adoption. Oral FMT offers a less invasive alternative, but the harsh gastric environment necessitates a protective delivery system. This research investigated how well microencapsulation with chitosan and chitosan-genipin safeguards Escherichia coli in conditions that simulate gastric transit. Microfluidic encapsulation generated uniform microcapsules, and simulated gastrointestinal analysis revealed superior stability for chitosan-genipin over chitosan alone. RNA sequencing and bioinformatics showed that chitosan-genipin significantly reduced simulated gastric fluid-induced transcriptomic disturbances in E. coli , lowering differentially expressed genes compared to chitosan or non-encapsulated samples controls. These findings suggest chitosan-genipin microencapsulation is a promising method for non-invasive and effective oral fecal microbiota transplant delivery.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: